Marfan edition · Most recent Marfan syndrome conclusions
Last updatedMonday, November 2, 20266:43 AM ET
Today's headlineThe Marfan Foundation's Science in Spain meeting is under way in Barcelona, with nearly 300 registrants from 23 countries (Oct 4-5). A re-analysis of the Pediatric Heart Network's losartan-versus-atenolol trial was published in 2026.
Marfan syndrome has no cure yet. Careful monitoring and aortic surgery prevent its most dangerous complication.
Cure Checker's conclusion · Oct 2026
Most recent cure information
There is no cure for Marfan syndrome, and no medicine approved specifically for it. The main danger is a widening of the aorta, the body's largest artery, which can tear. Today's care is regular imaging, a beta-blocker or a drug called an ARB, and well-timed surgery. Our view: the cure will come from correcting the faulty FBN1 gene early or rebuilding the aortic wall. Until then, finding Marfan early and watching the aorta closely is what saves lives.
ARB drugs slow aortic growth, modestly.In the AIMS trial, irbesartan slowed aortic root growth to 0.53 mm a year versus 0.74 mm on placebo, about 30% less. Losartan lowered growth in the COMPARE trial too (0.77 mm vs 1.35 mm over about three years).
Not better than beta-blockers: a reality check.In the Pediatric Heart Network trial of 608 children and young adults, losartan worked about as well as atenolol, not better. The 2022 U.S. guideline recommends either a beta-blocker or an ARB at the highest dose a patient can tolerate.
Surgery works well when timed right.In one 20-year series, valve-sparing aortic root replacement had early mortality of about 1%, with 91% of patients alive at 10 years and 76% at 20.
Fixing the gene: still in the lab.Base editing has corrected the FBN1 mutation in human cells and embryos, and lab-grown patient cells are revealing new targets. No human gene therapy for Marfan exists yet.
This is Cure Checker's editorial assessment of published evidence, not medical advice. Care decisions belong with a cardiologist and a Marfan-experienced medical team.
A possible missing link
Please read first. This is an AI-generated hypothesis, written by Cure Checker's AI from published research. It is speculation, not an established finding. It is not a recommendation, not a prediction that a cure exists, and not medical advice. No doctors or scientists have reviewed it, and it may be wrong. Never start, stop, change or delay any treatment because of it. Talk with your cardiologist.
What looks like it is working
Slowing the stretch. Pooling 7 randomized trials (1,442 people), ARB drugs roughly halved how fast the aortic root grew, and beta-blockers did about as well (Lancet, 2022). This slows the disease; it does not fix the weak tissue.
The gene type matters. Some FBN1 changes leave the body making less normal fibrillin-1 (haploinsufficiency). In over 6,000 adults, these changes carried about 2.6 times the risk of aortic problems seen with the other main type (Heart, 2025).
More healthy fibrillin helped mice. Adding an extra normal fibrillin-1 gene protected the aorta in Marfan mice (J Clin Invest, 2004). Mouse work also suggests the wall fails below a threshold level of working fibrillin (PNAS, 1999).
Where the links are missing
Treatment by gene type. In part of the Dutch COMPARE trial, losartan clearly slowed root growth only in people with haploinsufficient changes (Circ Cardiovasc Genet, 2015), but a Spanish trial's long-term follow-up found no such difference (JACC, 2018). Our inference: both were small subgroups; no trial was built to settle this.
Fixing the root cause. Base editing corrected one FBN1 mutation in human cells and embryos (Mol Ther, 2018), and skipping one part of the FBN1 message still let healthy skin cells form fibers in a dish (Int J Mol Sci, 2021). Our inference: neither has been tested in a living aorta, and we found no registered human trial aimed at the FBN1 gene itself.
How much is enough. A 2026 review calls the path from gene change to aortic disease incomplete (Cardiovasc Res, 2026). Our inference: no one knows how much extra fibrillin-1 a human aorta needs, or whether it can repair a stretched wall.
Our hypothesis
In people whose FBN1 change lowers the amount of normal fibrillin-1, could a treatment that turns up the healthy gene copy (one that does not yet exist) lift fibrillin-1 back above the level the aortic wall seems to need? Started in childhood, before the aorta widens, could it keep the aorta stable better than today's drugs?
What would prove it wrong: if raising fibrillin-1 from the healthy copy does not rebuild the wall's fibers or slow aortic widening in haploinsufficient mice.
Hypothesis written October 6, 2026. Cure Checker's AI will revisit it when major new evidence appears.
Latest studies & what they concluded
Newest first. Updated each morning as results, trial launches and papers are published.
Stem cells and aortic enlargement in Marfan mice (Heart Vessels)
In Marfan mice given a chemical (BAPN) that worsens aortic enlargement, researchers found changes in a type of stem cell (Sca1-positive) in the aorta wall, which shifted toward cells that make more scar-like collagen and activated TGF-beta signaling. The authors suggest restoring these cells' repair role could be a future approach. It is animal work and not a treatment for people.
Heart valve-ring gap and heart muscle in children with Marfan (J Am Soc Echocardiogr)
In 152 children with Marfan syndrome, a gap at the mitral valve ring (mitral annular disjunction) went with larger left-heart volumes and lower pumping strength, apart from valve leakage or prolapse. The authors suggest heart ultrasound checks for it may help spot early heart muscle changes. It shows a link, not a cause or a treatment.
Marfan versus Loeys-Dietz after aortic surgery (Aorta, meta-analysis)
Pooling 5 studies of 1,005 people (778 Marfan, 227 Loeys-Dietz), long-term survival after aortic surgery was similar. Loeys-Dietz carried a higher risk of dissection and repeat surgery, which the authors say supports lifelong imaging. The comparison was not adjusted for gene differences, so it is a guide, not proof.
The Marfan Foundation reports nearly 300 registrants from 23 countries at the Oct 4-5 scientific meeting. Talks covered aortic protection, a possible vaccine approach aimed at TGF-beta, and lung and pain research. These are presentations of early work, not proven treatments.
The Marfan Foundation's 12th International Symposium on Marfan, Loeys-Dietz, vascular Ehlers-Danlos and related syndromes, followed by a joint aortic session with the European Society of Cardiology.
Dangerous heart rhythms in adults with Marfan (Mayo Clinic cohort)
In 783 adults followed about 13 years, 74 (9.5%) had sustained ventricular tachycardia or fibrillation. Non-sustained VT, lower heart pumping strength, past heart surgery and leaky mitral valve were linked to it. A retrospective study, so it shows links, not cause.
ARBs and beta-blockers: individual-patient meta-analysis
Pooling the randomized trials, ARBs reduced the rate of aortic root enlargement by about half in people with Marfan, including those already on a beta-blocker.
No drug is approved specifically for Marfan. Doctors use blood-pressure medicines off-label to slow aortic growth, and surgery to replace the aortic root before it can tear.
Beta-blockers
Standard
Atenolol, propranolol and others · decades of use
Lower heart rate and the force of each beat, easing stress on the aorta. They have the longest track record, including in children and in pregnancy, and are still first-line in many centers.
Irbesartan
Positive trial
AIMS trial · The Lancet, 2019
A double-blind trial in children and young adults found aortic root growth of 0.53 mm a year on irbesartan versus 0.74 mm on placebo, about a 30% slowing, with the drug well tolerated.
Slowed aortic growth in adults (0.77 mm vs 1.35 mm over about three years) and worked about as well as atenolol in children and young adults. Not clearly better than beta-blockers.
Valve-sparing root surgery
Standard
David procedure · prophylactic surgery
Replaces the widened aortic root while keeping the patient's own valve. Surgery is generally advised once the root passes about 50 mm, or about 40 mm with a family history of dissection. In one long series, 91% were alive at 10 years.
Exercise study
Recruiting
Texas Children's Hospital & Stanford · ages 10–25
Studies how moderate exercise affects young people with Marfan, to give clearer activity advice.
Nutritional ketosis
Starting · 2026
Washington University · est. Mar 2026 to Mar 2028
Tests a ketogenic diet as a way to stabilize a chronic aortic dissection in Marfan, a new idea at an early stage.
Standard treatment today
Treatment
For
What it does
Regular imaging (echo, MRI or CT)
Everyone with Marfan
Tracks aortic size so surgery can be timed before it tears.
Beta-blocker or ARB
Most people
Slow aortic growth. 2022 U.S. guideline: either one at the highest tolerated dose.
Aortic root surgery
When the aorta reaches the threshold
Replaces the weak section. Valve-sparing techniques avoid lifelong blood thinners.
Eye, spine & chest care
As needed
Lens checks, bracing or surgery for scoliosis, and treatment of chest wall changes.
Pregnancy planning
Women with Marfan
Needs specialist cardiology and obstetric care because of added aortic risk.
Natural remedies & daily care
No supplement strengthens fibrillin or protects the aorta. The most useful daily steps are about managing blood pressure and activity safely. We rate each by the strength of evidence.
Strong expert consensusObservational / mixedNo evidence, or possible harm
Protecting the aorta
Keep blood pressure low
Lower pressure means less stress on the aortic wall. Medicines are the main tool, with a low-salt diet and weight management.
Avoid heavy lifting & contact sports
Heavy straining and collisions raise the risk to the aorta. Doctors usually advise avoiding them.
Moderate aerobic exercise
Generally encouraged at a gentle pace, such as walking or swimming. A trial is studying it in young people.
Promoted without evidence, or risky
Collagen, vitamin C & "connective tissue" supplements
No evidence they strengthen fibrillin or slow aortic growth.
Fluoroquinolone antibiotics
FDA safety communications link this antibiotic class to aortic aneurysm and dissection. Tell any prescriber you have Marfan.
Stimulants and decongestants
Can raise blood pressure and heart rate. Ask your doctor before using energy products or decongestants.
Be careful: carry a card or alert saying you have Marfan syndrome, and know the warning signs of aortic dissection: sudden severe chest or back pain. Call emergency services immediately.
Where to get care and support
Centers recognized for expertise in this condition, and communities of people living with it.
Where people find expert care
Boston Children's HospitalBoston, Massachusetts, USA
The principal investigator of the national trial comparing atenolol and losartan in children and young adults with Marfan syndrome is at this hospital.
These are centers recognized for expertise in this condition, not a ranking, and Cure Checker does not endorse or rate any facility. Outcomes depend on the individual. Ask your doctor which center fits your situation.
Support groups & communities
Marfan syndrome affects many parts of the body, and talking with others who've been through it helps. Most of these are free.
The Marfan Foundation community
Community
Patients · families · caregivers
Online community and local connections, with a way to reach others every day of the year.
Before you join: support groups share experiences, not medical advice. Check anything about treatment or activity with your doctor. Think about your privacy, and never share passwords or financial details. Cure Checker isn't affiliated with these groups.
How other countries treat Marfan syndrome
No country has approved a drug specifically for Marfan, so treatment looks similar worldwide: monitoring, a beta-blocker or ARB used off-label, and surgery. The big trials came from the Netherlands, the UK and the U.S.
What's available
Treatment
U.S.
EU
UK
Canada
Japan
S. Korea
China
Australia
Switz.
Drug approved for MarfanSpecific indication
None
None
None
None
None
None
None
None
None
Beta-blocker or ARB, off-labelGuideline care
2022 guideline
Used
Used
—
—
—
—
—
—
Used used off-label, or recommended in guidelinesNone no drug approved for Marfan— not verified for this report
Where the evidence came from
Netherlands
COMPARE
Losartan trial in adults
The COMPARE trial found that losartan reduced aortic root growth in adults with Marfan, with long-term follow-up published in the European Heart Journal.
A biological collection for Marfan and related syndromes is recruiting in Toulouse, building the samples researchers need to find new targets. It runs from 2021 into 2031.
A U.S. mouse study in Science shows losartan prevents aortic aneurysm in Marfan mice.
The Dutch COMPARE trial finds losartan reduces aortic root growth in adults.
The U.S.-led Pediatric Heart Network trial finds losartan no better than atenolol.
The UK-led AIMS trial shows irbesartan slows aortic growth.
The U.S. aortic disease guideline recommends a beta-blocker or an ARB for Marfan. A pooled meta-analysis follows in 2023.
New trials of exercise and ketosis start. The Marfan Foundation holds Science in Spain (October).
What causes Marfan syndrome
Marfan syndrome is caused by a change in the FBN1 gene, which makes fibrillin-1, a protein that gives connective tissue its strength and stretch. Weak connective tissue affects the heart and aorta, eyes, bones and joints.
Step 1 · The gene
One changed copy is enough
50% chancefor each child of a parent with Marfan
Common for a rare disease: about 1 in 5,000 people
Dominant: a parent with Marfan passes it on half the time. Some cases start as a new change.
Related conditions: Loeys-Dietz syndrome and vascular Ehlers-Danlos syndrome affect the aorta too
Step 2 · The tipping point
Connective tissue is weak
Fibrillin-1 forms the "scaffolding" of connective tissue
A faulty version also raises a growth signal called TGF-beta, which loosens tissue further
Step 3 · The damage
The aorta stretches
Aorta: the root, where the aorta leaves the heart, slowly widens
Heart valves: mitral and aortic valves can leak
Eyes: the lens can shift, and nearsightedness is common
Skeleton: tall height, long limbs and fingers, curved spine, chest wall changes
Step 4 · The result
Dissection risk
A widened aorta can tear (dissect) suddenly, which is a medical emergency
With monitoring and surgery in time, most of these emergencies can be prevented
The losartan story: a famous 2006 mouse study (Science) showed losartan stopped aortic growth, raising huge hopes. In people the effect has been real but modest, a lesson in how far a lab result can differ from a human trial.
Pediatric research (2026): a June 2026 re-analysis of the Pediatric Heart Network trial used a body-size measure of the aorta to compare losartan and atenolol more fairly.
New targets (Aug 2026): lab-grown blood-vessel cells from people with Marfan show impaired inflammatory resolution, a possible new drug target. This is early, preprint research.
Find a clinical trial
Live numbers and the newest entries from the world's main trial registries and medical databases. Most of this loads fresh each time you open the page.
Where Marfan trials are recruiting right now
Loading live data from ClinicalTrials.gov…
Drug trials with no U.S. site
Newest published clinical trials
PubMed · U.S. National Library of Medicine
Loading…
Newest Cochrane systematic reviews
Cochrane Database of Systematic Reviews, via PubMed
Loading…
Newest trials in the EU registry
EU Clinical Trials Information System
Newest UK & international registrations
ISRCTN registry
Loading…
FDA records for the medicines in this report
Medicine
Brand
FDA application
Original approval
From Drugs@FDA via FDA's openFDA service. Some older brands are missing from FDA's open data, and newly approved drugs can take a few weeks to appear. An approval may be for a different disease than this one.
Search every registry yourself
The WHO's ICTRP gathers trials from registries worldwide, including China, Japan, India, Iran, Australia and Brazil. Cochrane CENTRAL and OpenMD don't allow automated access, so they're linked here for you to search directly.
Sources
Everything this report is based on, grouped by section. Checked October 2, 2026.
The "COMPARE was Dutch, AIMS was UK-led" attributions, the 2013 date for COMPARE, the 2006 mouse study date, the growth-signal (TGF-beta) explanation, the fluoroquinolone and decongestant cautions, and the pregnancy and surgical-threshold details reflect the established published record and guidelines. Not every one has an individual citation here. Expert care centers: The Marfan Foundation's institution directory is self-reported and the Foundation does not endorse the listed hospitals, so it was not used as a designation. These entries rest on trial roles; the Hopkins and Washington University entries are listed sites only.